NYSE: IQV · Diagnostics & Research
IQVIA Holdings (IQV) fair value: undervalued or overvalued?
As of 28 Sep 2026, Faircurve's model values IQVIA Holdings (IQV) at $359.38 a share. The stock last closed at $258.21, which puts the model's fair value 39.2% above the price. On the model's bands that reads as Undervalued.
Revalued . Price is the close of 2 Oct 2026. IQVIA Holdings Inc.
Faircurve Insights · 28 Sep 2026
IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services. It caters to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific.
Faircurve's model valued IQVIA Holdings Inc. on 28 Sep 2026. The model's fair value was $359.38 a share, the midpoint of 2,000 simulations. The previous run on 19 Sep 2026 gave $369.50, so the fair value moved -2.7%. The calibrated range over 63 trading days was $301.51 to $438.20, built from the fair value, since there is no live options data for the stock. This range held the price 60% of the time at this horizon and the evidence grade was High.
The overall quality score was 56 out of 100 against comparable companies. The model compares it with Waters Corporation, IDEXX Laboratories, Inc., Illumina, Inc., Agilent Technologies, Inc., Mettler-Toledo International Inc., Quest Diagnostics Incorporated, and Medpace Holdings, Inc. The stock's median move around the last 8 earnings reports was 5.3%, ignoring direction.
Written from the figures on this page for the 28 Sep 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
What price range does the model give IQV?
The calibrated range for IQV over 63 trading days is $301.51 to $438.20. There is no live options data for this stock, so the range is built from the fair value and calibrated weekly against realised prices (n = 4,327 past valuations, refreshed 26 Sep 2026). Ranges built this way held the price 60% of the time at this horizon.
The price is below this range. For names with fair value 30%+ above price, the calibrated range has held the price 29% of the time over 63 trading days, and 71% ended below it; the typical move was +5.7%.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $290.62 to $434.76. In 87% of the simulations the fair value came out above the price the model ran on.
How does IQV score on business quality?
IQVIA Holdings's overall quality score is 56 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 36 | 9.4%ROIC | 16.2% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 90 | 1.90xFCF / net income | 1.09x |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analyst estimate revisions. | 56 | 5.9%Revenue growth, trailing | 4.9% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 59 | 0.3%Net buybacks / market value | 2.0% |
| Balance sheetNet debt to EBITDA and interest coverage. | 11 | 4.06xNet debt / EBITDA | 1.17x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 91 | 0.7 ptsEBITDA margin downside volatility, 5y | 1.4 pts |
How does IQV compare with similar companies?
The companies in diagnostics & research closest to IQVIA Holdings in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| WAT Waters Corporation | $425.21 | $329.03 | -22.6% | Overvalued |
| IDXX IDEXX Laboratories, Inc. | $518.39 | $486.42 | -6.2% | Fairly valued |
| ILMN Illumina, Inc. | $273.04 | $208.21 | -23.7% | Overvalued |
| A Agilent Technologies, Inc. | $167.78 | $161.23 | -3.9% | Fairly valued |
| MTD Mettler-Toledo International Inc. | $1,486.19 | $1,422.10 | -4.3% | Fairly valued |
| DGX Quest Diagnostics Incorporated | $233.33 | $280.88 | +20.4% | Undervalued |
| LH Labcorp Holdings Inc. | $308.49 | $303.65 | -1.6% | Low evidence grade |
| MEDP Medpace Holdings, Inc. | $599.47 | $680.99 | +13.6% | Fairly valued |
All diagnostics & research stocks ranked by gap to fair value
When does IQV report earnings, and how has the stock reacted?
IQVIA Holdings's next earnings report is scheduled for 3 Nov 2026. Companies can move their dates.
Options prices on 2 Oct 2026 imply a move of about 12.6% in either direction through the nearest expiry, about 48 days out, a window that includes the report. That is the size the market is pricing, not a direction.
How IQV moved around its last 8 earnings reports
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across these 8 reports, ignoring direction, was 5.3%.
| Report date | Two session move |
|---|---|
| 28 Jul 2026 | +16.1% |
| 5 May 2026 | +9.6% |
| 5 Feb 2026 | -7.4% |
| 28 Oct 2025 | +0.2% |
| 22 Jul 2025 | +22.2% |
| 6 May 2025 | +0.7% |
| 6 Feb 2025 | +1.3% |
| 31 Oct 2024 | -3.2% |
IQVIA Holdings at a glance
IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific.
- Market value
- $44.5B
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Revenue expected, next twelve months
- $18.2B
- Consensus revenue growth, next fiscal year
- +6.7%
- Analysts with estimates
- 14
- Beta to the US market
- 0.71
- First valued by Faircurve
- 1 May 2026
How the fair value is worked out: the model prices IQVIA Holdings on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 19 Sep 2026 the model's fair value for IQV was $369.50. As of 28 Sep 2026 it is $359.38, a change of -2.7%. The model revalues every stock it covers each week, and again after an earnings report.
Questions about IQVIA Holdings's valuation
Is IQVIA Holdings stock undervalued or overvalued?
On Faircurve's model, IQV reads as Undervalued as of 28 Sep 2026. The model's fair value is $359.38 a share against a last close of $258.21, a gap of +39.2%.
What is IQV's fair value?
$359.38 a share as of 28 Sep 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $290.62 to $434.76.
What price range does the model give IQV?
$301.51 to $438.20 over 63 trading days. Ranges built this way held the price 60% of the time across 4,327 past valuations, refreshed 26 Sep 2026.
When does IQVIA Holdings report earnings next?
The next report is scheduled for 3 Nov 2026. Companies can move their dates.
How much has IQV moved on past earnings reports?
Across its last 8 reports the median two session move was 5.3%, ignoring direction. The largest was +22.2% around the report of 22 Jul 2025.
How confident is the model in this valuation?
The model's evidence grade for IQV is high. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.